Kuchyne na miru

Latest

Pharmaceutical Native Advertising

A look into how native advertising works, what cost benefits they provide, and measuring their success.

Post-Launch Birthday: The Time to Refine

Following a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.

Product Development: The Optimizer’s Curse

Reoccurring disappointment in development portfolios—why it happens and how to mitigate it.

Product Launch: Five Paths Forward

Pharm Exec’s annual feature profiling a selection of notable biopharma brands focuses this year on new beginnings and new promise—spotlighting five products with compelling product launch stories.

Pharm Exec Video

Talking with Peter Barschdorff Vice President, Commercial Insights, GSK

Associate Editor, Christen Harm talks with Peter Barschdorff, Vice President, Commercial Insights, GSK , at the 2019 18th Annual eyeforpharma Philadelphia Conference, Expo & Awards.

Chatting with Jay Sabbah Senior Director, Marketing, GSK

Pharm Exec's Associate Editor, Christen Harm chats with Jay Sabbah, Senior Director, Marketing, GSK , at the 2019 18th Annual eyeforpharma Philadelphia Conference, Expo & Awards.

A Conversation with Greg Apostol, National Vice President, Key Account Management, Alkermes

Greg Apostol, National Vice President, Key Account Management, Alkermes, talks with Pharm Exec's Editorial Director Lisa Henderson, at the 2019 18th Annual eyeforpharma Philadelphia Conference, Expo & Awards.

New & Noteworthy

Accelerating Industry Consolidation Leaves Dwindling Choices for Patients & SME Firms

Rife M&A activity the life sciences harms competition and reduces choice, both for patients and for modest-sized biopharma firms seeking help with growing pharmacovigilance and regulatory filing requirements, writes Alan White.

Commercialization Imperatives for Success in Rare Diseases

To ensure patients have timely access to expensive new therapies, biopharma companies have to address commercialization challenges with innovative measures.

The Accelerated Product Launch Reality

Expedited reviews drive new imperative for iteration and quality data that enable agility and results. Meghan Oates-Zalesky reports.

“Sunshine” on Marketing, Research Payments Expands

As part of the Open Payments program expansion, drug and medical device manufacturers will have to report payments and other “transfers of value” to a broader range of health professionals.

From the Editor

Setting Your Launch Path

There are many factors involved in launching a drug but one prevailing goal: brand awareness. Bryan O’Malley shares some of today's key digital trends affecting that mission.

A Look Back & Forward on Innovation

In a sit-down with editors from our group publications, former FDA Commissioner Scott Gottlieb chatted with Pharm Exec on several topics, including the evolution of pricing and reimbursement for novel therapies—and the access fixes needed for future.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Who Will Head FDA?

Time is running out on Ned Sharpless’ term as FDA acting commissioner, generating much talk as the administration shows interest in naming a new head for the agency.

Setting Your Launch Path

There are many factors involved in launching a drug but one prevailing goal: brand awareness. Bryan O’Malley shares some of today's key digital trends affecting that mission.

Changing Drug Benefit Design & Transparency to Impact Drug Prices

Rick Kelly and Nisha Desai provide an overview of the “American Patients First” blueprint's four key strategies.

The Murky Outlook for Generic Drugs

Market consolidation limits sales, while legal challenges offset regulatory gains.

Pharm Exec's 18th Annual Industry Audit

Pharm Exec’s latest analysis of financial performance reveals that it’s those drugmakers maximizing the difference between the value and the cost of their capital investments that are delivering the most bang for the buck to shareholders.

Interviews

Emerging Biopharma Tackles the Opioid Crisis

Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies and the crisis worsens.

Leveraging Social Media in Pharma

In this Q&A, Emma Monks, VP of Crisis Intelligence at Crisp, discusses potential crisis points for the pharmaceutical industry.

Looking Back at NICE: Sir David Haslam

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

The Call to Cure: Geoff MacKay, AVROBIO

Pharm Exec speaks with Geoff MacKay, CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies and moving gene therapy into the mainstream.

Luxturna: A Vision for Curative Therapy Access

Pharm Exec highlights a recent fireside chat between Veeva’s Matt Wallach and Jeffrey Marrazzo, CEO of Luxturna maker Spark Therapeutics.

Regulatory

Who Will Head FDA?

Time is running out on Ned Sharpless’ term as FDA acting commissioner, generating much talk as the administration shows interest in naming a new head for the agency.

The Murky Outlook for Generic Drugs

Market consolidation limits sales, while legal challenges offset regulatory gains.

“Sunshine” on Marketing, Research Payments Expands

As part of the Open Payments program expansion, drug and medical device manufacturers will have to report payments and other “transfers of value” to a broader range of health professionals.

Product Data: Not Just for Regulators

Patients, clinicians, pharmacists and the wider public should be front of mind when evaluating priorities and steps towards Identification of Medicinal Products (IMDP) and other emerging standards, writes Frits Stulp.

piratecodex.us

http://profvest.com

читайте здесь www.profvest.com
lorem ipsum